Imcivree

BOSTON, MA, May 1, 2026 Rhythm Pharmaceuticals, Inc. announced that the European Commission has granted marketing authorization for IMCIVREE®...

Boston, March 26, 2026 In a significant advancement for rare disease therapeutics, Rhythm Pharmaceuticals has received a positive opinion...

BOSTON, March 19, 2026 Rhythm Pharmaceuticals announced that the U.S. Food and Drug Administration has approved Imcivree (setmelanotide) for...